Diabetes, Type I
Conditions
Keywords
prevention
Brief summary
Prophylactic administration of metabolically active insulin can prevent or delay clinical onset of diabetes in a high risk group of nondiabetic siblings as defined by positivity for autoantibodies against IA-2 (IA-2-A).
Detailed description
Hypotheses: Primary: Prophylactic administration of metabolically active insulin can prevent or delay clinical onset of diabetes in a high risk group of nondiabetic siblings as defined by positivity for autoantibodies against IA-2 (IA-2-A). Secondary: 1) Untreated siblings with positivity for IA-2-A develop clinical diabetes significantly faster than untreated offspring with the same marker positivity. 2) Plasma proinsulin levels increase disproportionately before clinical onset of Type 1 diabetes both in siblings and offspring. 3) Prophylactic administration of metabolically active insulin reduces the plasma proinsulin/C-peptide ratio in non-diabetic antibody positive siblings and offspring. 4) Prophylactic administration of metabolically active insulin reduces the presence and/or levels of diabetes-associated autoantibodies directed against islet cell components. Endpoints: Fasting glycemia; fasting and stimulated plasma C-peptide and proinsulin values; islet cell autoantibodies; incidence of hypoglycemia; body weight gain.
Interventions
DRUGActrapid HM
56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
Sponsors
Novo Nordisk A/S
AZ-VUB
Study design
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 39 Years
Healthy volunteers
Yes
Inclusion criteria
* Sibling/offspring of a Type 1 diabetic patient * in good general condition * age 5-39 years * fasting plasma glucose \<126 mg/dL AND an OGTT that is non-diabetic by 1997 ADA criteria (33): 1. Normal glycemia: * fasting plasma glucose \< 110 mg/dL and * 2 hour plasma glucose \< 140 mg/dL 2. Impaired Fasting Glucose (IFG): * fasting plasma glucose 110-125 mg/dL and * 2 hour plasma glucose \< 140 mg/dL 3. Impaired Glucose Tolerance (IGT): * fasting plasma glucose \<110 mg/dL and * 2 hour plasma glucose 140-199 mg/dL * at least positive for IA-2-A * absence of a protective DQ genotype: A4-B2/X or X/Y or X/X where X = A2-B3.3, A1-B1.9, A1-B1.2, A4-B3.1, A2-B2 or A4.23-B3.1 Y = A1-B1.1, A1-B2, A1-B1.AZH, A3-B2, A3-B3.1, A3-B3.3, A3-B4, A4-B4, A4.23-B4, A4-B3.2, A3-B1.1, A4-B3.3, A4-B1.1 or A4.23-B2 (32) * cooperative and reliable subject (age ≥ 14 yrs) / parents (age \< 14 yrs) giving informed consent by signature; the patient/parents should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of insulin therapy; early intervention with metabolically active insulin treatment should be identified as a clinical trial. Both parents should sign and agree with the protocol procedure.
Exclusion criteria
* diabetes by 1997 ADA criteria (33): * fasting plasma glucose ≥ 126 mg/dL, or * 2 hour plasma glucose ≥ 200 mg/dL * donation of blood during the study or within one month prior to screening * pregnancy or lactation in women * use of inadequate anticonception by female patients of childbearing potential * use of illicit drugs or overconsumption of alcohol (\> 3 beers/day) or history of drug or alcohol abuse * being legally incapacitated, having significant emotional problems at the time of the study, or having a history of psychiatric disorders * having received antidepressant medications during the last 6 months * treatment with immune modulating or diabetogenic medication (such as corticosteroids) * presently participating in another clinical study or having done so during the last 12 months * history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risks to the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting glycemia; | 2004 |
| fasting and stimulated plasma C-peptide and proinsulin values; | 2004 |
| islet cell autoantibodies; | 2004 |
| body weight gain. | 2004 |
Countries
Belgium
Outcome results
None listed